All News
LLDAS: Predicting Pregnancy Outcomes
Pregnancy in SLE is a high risk situation and active disease can lead to fetal loss, pre-term birth, IUGR and neonatal lupus syndromes. In a study by Dr. Michelle Petri and colleagues, they evaluated whether the LLDAS at the start of pregnancy was predictive of pregnancy outcome.
Read Article
IN GOUT: CARES study said febuxostat increases CV risk; Todays FAST study says No incr CV risk w/ FEB. In your Gout pt w/ CV hx, would you use febuxostat? #ACR2020
Dr. John Cush RheumNow ( View Tweet)
Following the results of the FAST trial, would you have any concerns about prescribing febuxostat if clinically indicated?
#ACR20 @RheumNow
David Liew drdavidliew ( View Tweet)
Just as a reminder of how we felt back then.
https://t.co/onIMqa5DAp
Also note, the hypogammaglob gap has widened a little (then 25 v 21, now 36 v 26).
Now we have the extended follow-up data, where no additional benefit was noted, do we still feel that excited? #ACR20 @RheumNow
David Liew drdavidliew ( View Tweet)
Improvement of enthesitis US scores consistent with bDMARD initiation/change
1⃣MASEI and OMERACT scores improved at 3 mo/6mo
2⃣Associated with clinical activity outcomes
@RheumNow #ACR20 Abs#1552 https://t.co/qnSEBaXrJo
Robert B Chao, MD doctorRBC ( View Tweet)
RITZAREM
(RTX vs AZA maintenance post RTX induction relapsing AAV)
what happened post-study?
After #ACR19, hope RTX confers ongoing benefit
Answer: no. Same decline
Is 1g q4m dosing not justified?
Does that mean RTX needs to be continued, and in whom?
#ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC
David Liew drdavidliew ( View Tweet)
Did you have diversity and inclusion and/or bias training during fellowship? #ACR20 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
GOUT: CARES study says febuxostat has high CV risk, new FAST study says no incr risk. Would you give FEB to a gout pt w/ CV risk?
Dr. John Cush RheumNow ( View Tweet)
When diagnosing Febrile, possible autoinflammatory, Stills disorders do you order genetic testing
Dr. John Cush RheumNow ( View Tweet)
Rheum Now shares Day 3 highlights from #ACR20.
https://t.co/xNv1fG97ib https://t.co/Psa8bRqlVh
Links:
Dr. John Cush RheumNow ( View Tweet)
Congratulations to House of DMARDs, our new @ACRheum 2020 Knowledge Bowl Champions!! 🏆 We are so proud!! @kmdsilvaMD @JonathanDauMD @NasrallahMazen #ACR20 https://t.co/iFaMRNB5D3
MGH Rheumatology MGHrheumatology ( View Tweet)
Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20
Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. 31/33 patients continue in OLE https://t.co/kVQWN1s8Zy
The Lancet Rheumatology TheLancetRheum ( View Tweet)
These kind of studies must be done, but this result is to nobody’s surprise! #PedsRheum
Let’s keep working together to move the bar towards recognition that #sJIA and #AOSD are a single condition that can affect people of all ages! https://t.co/qzbgeKPlqw
Michael Ombrello MichaelOmbrello ( View Tweet)
Gout has more comorbidities than RA & PsA #1466 Half of respondents are correct @RheumNow @CRASCRRheum #ACR20 https://t.co/hjwYvCFJPk
Janet Pope Janetbirdope ( View Tweet)
Join now. Free to #ACR20 attendees. Women leaders in rheumatology @RheumNow @CRASCRRheum https://t.co/nIqZ8qTINY
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Awesome succinct guidelines!#acrbest #acr20 @RheumNow https://t.co/lzLykOY8G0
alexa meara lexmeara ( View Tweet)
VEXAS! Hot topic of the year #ACR2020 ABS#1953 @RheumNow https://t.co/RIQKsoWbHe
Bella Mehta bella_mehta ( View Tweet)
Mavrilimumab (anti GM-CSF receptor α Mab) efficacious in maintaining disease remission in GCA pts.
Phase 2 trial (n=70)
1⃣Disease flare 19% in tx vs. 46% in PBO at 26wk
2⃣Sustained remission 83% vs. 50% in PBO
3⃣Similar AE in both groups
@RheumNow #ACR20 Abs#L06 https://t.co/LqiNKJffFo
Robert B Chao, MD doctorRBC ( View Tweet)
@RheumNow #ACR20 Abs L08 Prospective 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat was not associated w/increased risk of death compared w/allopurinol. 222 (7·2%) pts died in the febuxostat group compared to 263 (8·6%) in the allopurinol group
Olga Petryna DrPetryna ( View Tweet)